Compare Invesco Solar ETF (TAN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Solar ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco Solar ETF trades at $43.67 (market cap $894.08M), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 11.3× Invesco Solar ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Solar ETF for 34 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| TAN | XBI | |
|---|---|---|
Market Cap | $894.08M | $10.11B |
Volume | 370,994 | 12,903,266 |
Sector | Sector/Thematic | Broad Market / Factor |
52-Week High | $73.95 | $169.55 |
52-Week Low | $43.00 | $104.99 |
Typical Hold Time | 34 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TAN trades at $43.6, up 0.16% on the day, amid a bearish technical signal with moving averages and key indicators like ADX signaling sell conditions. The ETF faces headwinds from high borrowing costs impacting solar project financing, as noted in recent news. Financial ratios are unavailable, but the fund's high expense ratio of 0.7% and historical volatility are points of concern for investors.
Outlook remains cautious due to sector-specific risks like interest rate sensitivity and market saturation. Investment opportunities exist for those bullish on long-term solar adoption, but risks include policy uncertainty and cost pressures. Analyst sentiment is mixed, with some highlighting underperformance versus broader markets.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
